PT-141: Benefits & Research
Part of the PT-141 Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
FDA-Approved for HSDD
PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first medication to target sexual desire through the central nervous system rather than vascular mechanisms. Phase 3 trials (RECONNECT) showed statistically significant improvements in desire scores and reductions in distress related to low desire.
Central Desire Enhancement
Unlike PDE5 inhibitors (Viagra, Cialis) that increase blood flow, PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, enhancing sexual desire and motivation through dopaminergic pathways. This central mechanism makes it effective for desire disorders where physical arousal is not the issue.
Research in Males
While FDA-approved only for premenopausal women, research shows PT-141 also enhances sexual desire and erectile function in men, including those who do not respond to PDE5 inhibitors. Studies demonstrated improved erection quality in men with erectile dysfunction through the central MC4R pathway.